Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6563216 | 0.90 | KIF11 (0.32) | ESR1ESR2 | |
| SCHEMBL8996052 | 0.85 | MAPK1 (0.36) | MAPK1ALDH1A1ALOX15CYP2D6DRD2 | |
| SCHEMBL20176041 | 0.84 | CYP2D6 (0.35) | MAPK1ALDH1A1ALOX15CYP2D6DRD2 | |
| SCHEMBL6724604 | 0.83 | CASR (0.37) | ALDH1A1CYP2D6CYP3A4GRM1RAB9A | |
| SCHEMBL28451515 | 0.83 | TSHR (0.40) | ALDH1A1 | |
| SCHEMBL10107622 | 0.81 | CTSK (0.31) | RAB9ANPSR1KMT2A | |
| SCHEMBL10516000 | 0.81 | SQOR (0.35) | MAPK1ALDH1A1ALOX15CYP3A4KDM4E | |
| SCHEMBL28447850 | 0.81 | MEN1 (0.39) | MAPK1ALDH1A1ALOX15CYP2D6CYP3A4 | |
| SCHEMBL3709877 | 0.81 | APP (0.33) | — | |
| SCHEMBL28454941 | 0.80 | CA12 (0.38) | MAPK1ALDH1A1ALOX15CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108840821-B | Preparation and synthesis method of cobalt complex | 合肥工业大学 | 2021-05-25 | — | — | CN | disclosed |
| WO-2020207129-A1 | PREPARATION AND USE OF AN AMMONIUM SALT | 合肥祥晨化工有限公司 | 2020-10-15 | — | — | WO | disclosed |
| CN-107840857-B | Silicon cyanation reaction method for catalyzing ketone by borohydride | 杭州师范大学 | 2020-05-29 | — | — | CN | disclosed |
| CN-101039898-B | Titanium compound and process for producing optically active cyanohydrins | MITSUI CHEMICALS INC | 2012-01-11 | — | — | CN | disclosed |
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
| US-7732544-B2 | Titanium compound and process for producing optically active cyanohydrins | MITSUI CHEMICALS, INC. (JP) | 2010-06-08 | — | — | US | disclosed |
| EP-1806336-B1 | TITANIUM COMPOUND AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRINS | MITSUI CHEMICALS INC (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-20070265463-A1 | Titanium Compound and Process for Producing Optically Active Cyanohydrins | MITSUI CHEMICALS, INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| CN-101039898-A | Titanium compound and process for producing optically active cyanohydrins | MITSUI CHEMICALS INC (JP) | 2007-09-19 | — | — | CN | disclosed |
| EP-1806336-A1 | TITANIUM COMPOUND AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRINS | Mitsui Chemicals, Inc. (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-6677461-B2 | CYANOSILATION CATALYST | JAPAN AS REPRESENTED BY PRESIDENT OF THE UNIVERSITY OF TOKYO (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030119659-A1 | Ligands and asymmetric catalysts made by using the same | JAPAN AS REPRESENTED BY PRESIDENT OF THE UNIVERSITY OF TOKYO (JP) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | MAPK1 276/4885ALDH1A1 1585/4885ALOX15 4220/4885 |
| US-20030119659-A1 | Ligands and asymmetric catalysts made by using the same | AP2A1, AP3D1, AP3M1 | MAPK1 2168/4885ALDH1A1 492/4885ALOX15 4798/4885 |
| US-20070265463-A1 | Titanium Compound and Process for Producing Optically Active Cyanohydrins | WNT1, C3AR1, TDO2 | MAPK1 1898/4885ALDH1A1 1745/4885ALOX15 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.